Clinical Trial Update: Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma [Phase 1]

View source ↗

Summary

Reports that the Phase 1 trial of TJ011133 in relapsed/refractory advanced Solid Tumor and Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• TJ011133

Snippet

Sponsor: I-Mab Biopharma US Limited | Conditions: Solid Tumor, Lymphoma | Phase 1 | Status: COMPLETED